TRAW Stock Analysis: Buy, Sell, or Hold?
TRAW - Traws Pharma, Inc. Common Stock
$0.49
-0.03 (-6.13%)
▼
5d:
-27.26%
30d:
-43.31%
90d:
-59.99%
WAIT
LOW Confidence
Analysis Updated: Jul 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
17d
Get Alerted When TRAW Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TRAW is down 27.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TRAW is down 27.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TRAW is currently trading at $0.49, which is considered oversold relative to its 30-day fair value range of $0.61 to $0.84.
Technical Outlook: Technically, TRAW is in a strong downtrend. Immediate support is located at $0.46, while resistance sits at $0.77. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: TRAW has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $1.00 (+92.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TRAW is in a strong downtrend. Immediate support is located at $0.46, while resistance sits at $0.77. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: TRAW has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $1.00 (+92.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.61 -
$0.84
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.1%)
- BULLISH: Trading 92.3% below Wall St target ($1.00)
- WARNING: Recommendation downgraded due to -27.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.61 -
$0.84
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.46
Resistance Level
$0.77
Current Trend
Strong Downtrend
Technical data as of
Jul 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.26
Wall Street Target
$1.00
(+92.3%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 26, 2026 4:23 AM ET
Data refreshes hourly during market hours. Next update: 5:23 AM
Data refreshes hourly during market hours. Next update: 5:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRAW showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 53 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$301 | 54 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 57 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 51 HOLD |
|
CNTA
Centessa Pharmaceuticals… |
STRONG BUY
11 analysts |
$44 | 61 BUY |